ENvue Medical

FEED

Medical - Specialties · Healthcare

Price

$0.38

-0.01 (-2.11%)

Market Cap

$413,818

Exchange

NASDAQ Global Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Jul 25, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+7405.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11K (2021) → 858K (2025)

ENvue Medical is a small medical device company focused on developing imaging and guidance technology used during medical procedures. Its products are designed to help doctors see more clearly inside the body in real time, improving accuracy during minimally invasive treatments. The company targets hospitals and interventional specialists as its primary customers.

ENvue Medical generates revenue through medical device sales and related services, though the company is currently in an early commercial stage. Its deeply negative operating margin and negative gross margin signal that it is spending far more than it earns, which is common for pre-revenue or early-revenue medical device companies. The main risk is that the company must raise additional capital to fund operations while simultaneously proving its technology works well enough to win adoption from hospitals and physicians in a competitive medical imaging market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-36.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$2M/ year

↑ Rising (+94% vs prior year)

69.0% of revenue

3.8x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

0.8%ownership

Relatively low insider ownership

Cash Runway

~2 months

$2M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

ENvue Medical is putting 69% of revenue into R&D and that number is rising. That's 3.8x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-8.4%

Thin — -8.4% gross margin

Operating Margin

-568.3%

Losing money on operations — -568.3%

ROCE

-11.2%

Weak — -11.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-18.1%

Shrinking sales (-18.1% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-569.1%

Burning cash (-569.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.04

Conservative — low debt load (0.04)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial